このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Multimodal Assessment of Neuromuscular Electrical Stimulation (NMES) Effects on Respiratory and Peripheral Muscles in Chronic Obstructive Pulmonary Disease (COPD) (NMES in COPD)

2026年11月11日 更新者:Universitas Padjadjaran

Comparative Effects of Targeted Neuromuscular Electrical Stimulation (NMES) on Respiratory and Peripheral Muscles in Patients With Chronic Obstructive Pulmonary Disease (COPD): A Multimodal Assesment Using Diaphragm Ultrasound and Plasma Biomarkers (Interleukin-6 and Insulin-like Growth Factor- 1)

The goal of this clinical trial is to learn if targeted neuromuscular electrical stimulation (NMES) can treat respiratory and peripheral muscle weakness in patients with chronic obstructive pulmonary disease (COPD). The main questions it aims to answer are:

  • Does targeted NMES improve diaphragm thickening fraction and excursion as measured by diaphragm ultrasound?
  • What are the comparative effects of targeted NMES on plasma biomarkers, specifically Interleukin-6 (IL-6) and Insulin-like Growth Factor-1 (IGF-1)? Researchers will compare three groups: the first intervention group receiving intercostal NMES combined with Pursed-Lip Breathing (PLB), the second intervention group receiving quadriceps NMES combined with PLB, and a control group receiving sham upper trapezius NMES combined with PLB, to see if targeted NMES provides superior improvements in respiratory and peripheral muscle function.

Participants will:

  • Undergo baseline screening, including a diaphragm ultrasound and a blood draw for plasma biomarkers (IL-6 and IGF-1)
  • Be randomly assigned to one of the three groups to receive either intercostal NMES, quadriceps NMES, or sham upper trapezius NMES, all combined with Pursed-Lip Breathing exercises
  • Complete a post-intervention assessment involving repeat ultrasound imaging and biomarker analysis to evaluate muscle and systemic changes

調査の概要

詳細な説明

Chronic Obstructive Pulmonary Disease (COPD) is characterized by chronic airflow limitation and progressive respiratory and peripheral muscle dysfunction. While pulmonary rehabilitation is a cornerstone of management, severe breathlessness often limits a patient's exercise tolerance. Neuromuscular Electrical Stimulation (NMES) offers an alternative modality to train specific muscle groups without inducing severe dyspnea. However, the comparative efficacy of stimulating respiratory muscles versus peripheral muscle groups requires deeper investigation using precise physiological and biochemical markers.

This study utilizes a three-arm randomized controlled design to evaluate and compare the localized and systemic effects of targeted NMES. The mechanical properties of the respiratory system will be monitored using diaphragm ultrasound, focusing on active contractility and movement. Concurrently, systemic inflammation and muscle anabolic responses will be analyzed through plasma biomarkers to understand the underlying biomolecular pathways.

Upon meeting the eligibility criteria and providing written informed consent, the 45 participants will be randomly assigned to one of three study arms in a 1:1:1 ratio. All participants will undergo a standardized baseline assessment. Following the allocation, each group will complete their designated 8-week intervention protocol consisting of 3 sessions per week (total of 24 sessions) concurrently with Pursed-Lip Breathing (PLB) training. A comprehensive post-intervention reassessment will be conducted immediately following the final session to determine the comparative physiological and biochemical outcomes.

研究の種類

介入

入学 (推定)

45

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • West Java
      • Bandung、West Java、インドネシア
        • 募集
        • Faculty of Medicine Universitas Padjadjaran

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

40年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients diagnosed with stable Chronic Obstructive Pulmonary Disease (COPD), GOLD spirometric grade 2-4 (post-bronchodilator FEV1/FVC <0.70 with FEV1 <80% predicted), confirmed by a pulmonologist.
  • Age ≥ 40 years old.
  • Willing to participate in the study and sign the written informed consent form.

Exclusion Criteria:

  • Recent thoracic or abdominal surgery, pneumothorax, or a history of spontaneous pneumothorax.
  • Participation in other structured respiratory muscle training or pulmonary rehabilitation programs that may confound the study results.
  • Presence of neuromuscular, bulbar, laryngeal, or other disorders that may independently impair respiratory muscle function.
  • Use of a cardiac pacemaker or any metal/electronic implant at the intended stimulation area.
  • Diagnosis of heart failure classified as NYHA (New York Heart Association) class III-IV.
  • Presence of skin lesions, open wounds, or active dermatitis in the intended electrode placement areas.
  • Current use of systemic (oral) corticosteroids or history of use within 4 weeks prior to enrollment.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Intercostal NMES + PLB

Participants receive targeted NMES to the intercostal muscles combined with Pursed-Lip Breathing (PLB) exercises. The protocol is administered 3 times per week for 8 weeks.

Intercostal Neuromuscular Electrical Stimulation (NMES) is a procedure that uses small electrical impulses delivered through electrodes on the skin to stimulate motor nerves and cause passive muscle contractions which will be applied to the intercostal muscles

Pursed-lip breathing is a simple respiratory exercise that involves inhaling slowly through your nose and exhaling gently through tightly puckered or "pursed" lips (as if whistling or blowing out a candle).

実験的:Quadriceps NMES + PLB

Participants receive targeted NMES to the quadriceps muscles combined with Pursed-Lip Breathing (PLB) exercises. The protocol is administered 3 times per week for 8 weeks.

Pursed-lip breathing is a simple respiratory exercise that involves inhaling slowly through your nose and exhaling gently through tightly puckered or "pursed" lips (as if whistling or blowing out a candle).

Quadriceps Neuromuscular Electrical Stimulation (NMES) is a procedure that uses small electrical impulses delivered through electrodes on the skin to stimulate motor nerves and cause passive muscle contractions which will be applied to the quadriceps muscles

プラセボコンパレーター:Sham NMES + PLB

Participants receive sham NMES to the upper trapezius muscles combined with Pursed-Lip Breathing (PLB) exercises. The protocol is administered 3 times per week for 8 weeks.

Pursed-lip breathing is a simple respiratory exercise that involves inhaling slowly through your nose and exhaling gently through tightly puckered or "pursed" lips (as if whistling or blowing out a candle).

Sham Neuromuscular Electrical Stimulation (NMES) is a control procedure that delivers minimal electrical impulses via transcutaneous skin patches to the upper trapezius muscles, generating only a mild tingling sensation as a placebo effect without triggering any passive muscle contractions.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Diaphragm Excursion (DE)
時間枠:Baseline (Week 0) and post-intervention (Week 8)

Measured via B-mode or M-mode transabdominal ultrasound during quiet and deep breathing to evaluate the distance the diaphragm travels vertically. A higher excursion value indicates better diaphragmatic mobility.

Baseline (Week 0) and post-intervention (Week 8)
Diaphragm Thickening Fraction (TF)
時間枠:Baseline (Week 0) and post-intervention (Week 8)

Calculated using the formula: [(Thickness at end-inspiration - Thickness at end-expiration) / Thickness at end-expiration] x 100%. Measured via high-frequency linear ultrasound at the zone of apposition to assess diaphragmatic contractile function.

Baseline (Week 0) and post-intervention (Week 8)

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Plasma Interleukin-6 (IL-6) Levels
時間枠:Baseline (Week 0) and post-intervention (Week 8)

Measured via Enzyme-Linked Immunosorbent Assay (ELISA) from venous blood samples to evaluate systemic inflammatory profiles. Decreased levels indicate a reduction in systemic inflammation.

Baseline (Week 0) and post-intervention (Week 8)
Change in Plasma Insulin-like Growth Factor-1 (IGF-1) Levels
時間枠:Baseline (Week 0) and post-intervention (Week 8)

Measured via Enzyme-Linked Immunosorbent Assay (ELISA) from venous blood samples to evaluate muscle anabolic activity and systemic growth factor response. Increased levels indicate an improved anabolic state.

Baseline (Week 0) and post-intervention (Week 8)

その他の成果指標

結果測定
メジャーの説明
時間枠
Six-Minute Walk Test (6MWT) Distance
時間枠:Baseline (Week 0) and post-intervention (Week 8)

Measured by the total distance in meters that a participant can walk quickly on a flat, hard surface in a period of 6 minutes. It evaluates functional exercise capacity.

Baseline (Week 0) and post-intervention (Week 8)
Modified Medical Research Council (mMRC) Dyspnea Scale
時間枠:Baseline (Week 0) and post-intervention (Week 8)

A questionnaire used to rate the baseline dyspnea (breathlessness) on a scale from 0 (breathless only with strenuous exercise) to 4 (too breathless to leave the house). Lower scores indicate less respiratory disability.

Baseline (Week 0) and post-intervention (Week 8)
COPD Assessment Test (CAT) Score
時間枠:Baseline (Week 0) and post-intervention (Week 8)

An 8-item questionnaire measuring the health status impairment in COPD patients. Scores range from 0 to 40, where higher scores signify a worse health status and severe impact of COPD on the patient's life.

Baseline (Week 0) and post-intervention (Week 8)
Modified Borg Scale (MBS) for Dyspnea
時間枠:Baseline (Week 0) and post-intervention (Week 8)

A categorical scale ranging from 0 (no breathlessness at all) to 10 (maximal breathlessness) used to assess the patient's perceived level of shortness of breath during functional activity or rest.

Baseline (Week 0) and post-intervention (Week 8)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2027年10月1日

研究の完了 (推定)

2028年3月1日

試験登録日

最初に提出

2026年10月26日

QC基準を満たした最初の提出物

2026年10月26日

最初の投稿 (実際)

2026年11月2日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be made publicly available to protect participant privacy

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する